Doctored
Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wish list failed.
Follow podcast failed
Unfollow podcast failed
Pre-order Now for $25.08
No default payment method selected.
We are sorry. We are not allowed to sell this product with the selected payment method
-
Narrated by:
-
Lyle Blaker
-
Written by:
-
Charles Piller
About this listen
For listeners of Empire of Pain and Dopesick, an arresting deep dive into how Alzheimer’s disease treatment has been set back by corrupt researchers, negligent regulators, and the profit motives of Big Pharma.
Nearly seven million Americans live with Alzheimer’s disease, a tragedy that is already projected to grow into a $1 trillion crisis by 2050. While families suffer and promises of pharmaceutical breakthroughs keep coming up short, investigative journalist Charles Piller’s Doctored shows that we’ve quite likely been walking the wrong path to finding a cure all along—led astray by a cabal of self-interested researchers, government accomplices, and corporate greed.
Piller begins with a whistleblower—Vanderbilt professor Matthew Schrag—whose work exposed a massive scandal. Schrag found that a University of Minnesota lab led by a precocious young scientist and a Nobel Prize–rumored director delivered apparently falsified data at the heart of the leading hypothesis about the disease. Piller’s revelations of Schrag’s findings stunned the field and the public.
From there, based on years of investigative reporting, Doctored exposes a vast network of deceit and its players, all the way up to the FDA. Piller uncovers evidence that hundreds of important Alzheimer’s research papers are based on false data. In the process, he reveals how even against a flood of money and influence, a determined cadre of scientific renegades have fought back to challenge the field’s institutional powers in service to science and the tens of thousands of patients who have been drawn into trials to test dubious drugs. It is a shocking tale with huge ramifications not only for Alzheimer’s disease, but for scientific research, funding, and oversight at large.